Funding for this research was provided by:
University of Sheffield
Received: 19 March 2019
Accepted: 28 May 2019
First Online: 21 June 2019
Compliance with ethical standards
: PC has received speaker fees from Amgen, Lily, MSD, Novartis, Pfizer, and Roche, and report travel expenses from Amgen and MSD, outside the submitted work. NCH reports personal fees, consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare, and Internis Pharma, outside the submitted work. HJ and EL have nothing to disclose. ML has received lecture fees from Amgen, Lilly, Meda, Renapharma, and UCB Pharma, and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, and Consilient Health, outside the submitted work. JAK reports grants from UCB, grants from Amgen, and grants from Radius Health, outside the submitted work. EVM has received consultancy/lecture fees/grant funding/honoraria from ActiveSignal, AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Gilead, GSK, Hologic, Internis, Lilly, Medtronic, Merck, Novartis, Pfizer, Radius Health, Redx Oncology, Roche, Sanofi-Aventis, Servier, Synexus, Tethys, UCB, Viiv, Warner Chilcott, I3 Innovus, and Unilever, all outside the submitted work. NCH, HJ, ML, JAK, and EVM are members of the FRAX development team but derive no financial benefit.